[Semaglutide for Heart Failure with Preserved Ejection Fraction]
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M
. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37):3627-3639.
DOI: 10.1093/eurheartj/ehad195.
View
2.
Lincoff A, Brown-Frandsen K, Colhoun H, Deanfield J, Emerson S, Esbjerg S
. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389(24):2221-2232.
DOI: 10.1056/NEJMoa2307563.
View
3.
Perkovic V, Tuttle K, Rossing P, Mahaffey K, Mann J, Bakris G
. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024; 391(2):109-121.
DOI: 10.1056/NEJMoa2403347.
View
4.
Kosiborod M, Abildstrom S, Borlaug B, Butler J, Rasmussen S, Davies M
. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023; 389(12):1069-1084.
DOI: 10.1056/NEJMoa2306963.
View
5.
Kosiborod M, Petrie M, Borlaug B, Butler J, Davies M, Hovingh G
. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024; 390(15):1394-1407.
DOI: 10.1056/NEJMoa2313917.
View